Key Points
- Insider sale: James Berkshire sold 2,668 IQVIA shares for approximately $697,228 at an average price of $261.33, reducing his position by 19.68%.
- Strong quarterly results: IQVIA reported quarterly EPS of $3.15, above the $3.03 consensus estimate, while revenue rose 8.7% year over year to $4.37 billion.
- Analyst outlook remains positive: IQVIA has a consensus “Moderate Buy” rating, with analysts citing a consensus price target of $243.62; institutional investors own 89.62% of the stock.
IQVIA Holdings Inc. (NYSE:IQV - Get Free Report) insider James Berkshire sold 2,668 shares of the business's stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $261.33, for a total transaction of $697,228.44. Following the sale, the insider directly owned 10,890 shares of the company's stock, valued at approximately $2,845,883.70. The trade was a 19.68% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
IQVIA Price Performance
Shares of IQVIA stock opened at $267.34 on Friday. IQVIA Holdings Inc. has a one year low of $154.50 and a one year high of $271.80. The stock's fifty day moving average is $230.54 and its 200 day moving average is $192.66. The stock has a market cap of $44.00 billion, a P/E ratio of 33.17, a P/E/G ratio of 2.32 and a beta of 1.18. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.71 and a current ratio of 0.71.
IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.03 by $0.12. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The business had revenue of $4.37 billion during the quarter, compared to analyst estimates of $4.30 billion. During the same quarter in the previous year, the company posted $2.81 earnings per share. IQVIA's revenue for the quarter was up 8.7% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Sell-side analysts anticipate that IQVIA Holdings Inc. will post 11.57 earnings per share for the current year.
Analyst Ratings Changes
Several research firms have commented on IQV. BMO Capital Markets increased their price objective on shares of IQVIA from $210.00 to $270.00 and gave the company an "outperform" rating in a report on Wednesday, July 29th. Barclays reissued an "overweight" rating on shares of IQVIA in a research note on Tuesday, July 28th. Deutsche Bank Aktiengesellschaft set a $240.00 price objective on IQVIA in a report on Thursday, July 9th. HSBC reiterated a "buy" rating and set a $240.00 target price on shares of IQVIA in a research report on Monday, July 6th. Finally, JPMorgan Chase & Co. boosted their price target on shares of IQVIA from $225.00 to $285.00 and gave the stock an "overweight" rating in a research report on Wednesday, July 29th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have given a Hold rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $243.62.
Get Our Latest Report on IQVIA
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. International Assets Investment Management LLC purchased a new stake in IQVIA during the fourth quarter valued at approximately $27,000. Compass Financial Management LLC bought a new stake in shares of IQVIA in the 2nd quarter valued at approximately $27,000. Gilpin Wealth Management LLC purchased a new position in shares of IQVIA in the 4th quarter worth approximately $27,000. CrossGen Wealth LLC bought a new position in shares of IQVIA during the 4th quarter valued at approximately $28,000. Finally, Financial Freedom LLC purchased a new stake in shares of IQVIA in the first quarter valued at $25,000. Hedge funds and other institutional investors own 89.62% of the company's stock.
IQVIA Company Profile
(
Get Free Report)
IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.
IQVIA's principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
